Genmab — Juni 2017
-
Nyt studie: To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) & dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk population of myeloma patients, to take forward into a phase III trial compared to standard treatment.
-
-
God morgen.

-
Kan ikke finde bava-chatten https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=439942013&sourcecode=ddk
-
God morgen, Dax og Nasdaq er grønne her til morgen. Lad os håbe på en god dag til os alle!

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind